Deniz M, Kaufmann J, Stahl A, Gundelach T, Janni W, Hoffmann I, et al. In vitro model for DNA double-strand break repair analysis in breast cancer reveals cell type-specific associations with age and prognosis. FASEB J. 2016;30:3786-3799 pubmed

Ongaratti B, Silva C, Trott G, Haag T, Leães C, Ferreira N, et al. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. Braz J Med Biol Res. 2016;49:e5125 pubmed publisher

Tökés A, Szász A, Geszti F, Lukács L, Kenessey I, Turányi E, et al. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases. J Clin Pathol. 2015;68:274-82 pubmed publisher

Javle M, Churi C, Kang H, Shroff R, Janku F, Surapaneni R, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58 pubmed publisher

Churi C, Shroff R, Wang Y, Rashid A, Kang H, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE. 2014;9:e115383 pubmed publisher

Milosević J, Klinge J, Borg A, Foukakis T, Bergh J, Tobin N. Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. BMC Cancer. 2013;13:473 pubmed publisher

Gros S, Kurschat N, Drenckhan A, Dohrmann T, Forberich E, Effenberger K, et al. Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS ONE. 2012;7:e47287 pubmed publisher

Schrohl A, Pedersen H, Jensen S, Nielsen S, Brunner N. Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology. 2011;59:975-83 pubmed publisher

Karihtala P, Kauppila S, Soini Y, Arja Jukkola Vuorinen -. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer. 2011;11:262 pubmed publisher

Jonckheere N, Fauquette V, Stechly L, Saint Laurent N, Aubert S, Susini C, et al. Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression. Br J Cancer. 2009;101:637-44 pubmed publisher

Barros Silva J, Leitao D, Afonso L, Vieira J, Dinis Ribeiro M, Fragoso M, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100:487-93 pubmed publisher

Schindlbeck C, Kampik T, Janni W, Rack B, Jeschke U, Krajewski S, et al. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res. 2005;7:R1174-85 pubmed

Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7:R465-9 pubmed

Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7:R93-100 pubmed

Hernes E, Fossa S, Berner A, Otnes B, Nesland J. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer. 2004;90:449-54 pubmed

Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer. 2003;89:899-906 pubmed

Koukourakis M, Giatromanolaki A, Galazios G, Sivridis E. Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?. Br J Cancer. 2003;88:711-7 pubmed

McKay J, Loane J, Ross V, Ameyaw M, Murray G, Cassidy J, et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer. 2002;86:568-73 pubmed

Gilbertson R, Wickramasinghe C, Hernan R, Balaji V, Hunt D, Jones Wallace D, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer. 2001;85:705-12 pubmed